Orforglipron
Orforglipron is an oral, non-peptide (small-molecule) GLP-1 receptor agonist developed by Eli Lilly. Its trials and regulatory status are tracked here from official sources.
- Editorial attention
- Emerging
- Tracked this week
- 3
- Sources this week
- 3
- Last activity
- 17 hrs ago
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Orforglipron at a glance
- About this topic
- Orforglipron is an oral, non-peptide (small-molecule) GLP-1 receptor agonist developed by Eli Lilly. Its trials and regulatory status are tracked here from official sources.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: Results posted on ClinicalTrials.gov: ACHIEVE-5 (A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin…) (opens the source in a new tab) (ClinicalTrials.gov (U.S. National Library of Medicine), Sep 30, 2026)
- Key facts from tracked records
- 20 clinical trials tracked from ClinicalTrials.gov
What’s the latest on Orforglipron?
0 totalNo briefings on this topic yet. Official records and trials below are updated continuously.
What do the official records show?
Primary sources and peer-reviewed research- Results posted on ClinicalTrials.gov: ACHIEVE-5 (A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin…) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Conditions: Type 2 Diabetes. Interventions: Orforglipron; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
- Results posted on ClinicalTrials.gov: ACHIEVE-3 (A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately…) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Conditions: Type 2 Diabetes. Interventions: Orforglipron; Semaglutide. Investigational: trial-stage therapies are not approved for the use studied.
- Results posted on ClinicalTrials.gov: ATTAIN-2 (A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes) (opens the source in a new tab)
Phase 3, Eli Lilly and Company. Conditions: Obesity; Overweight; Type 2 Diabetes. Interventions: Orforglipron; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
Which clinical trials are being tracked?
All trials- ATTAIN-NOW: A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company. Conditions: Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal. Investigational — not approved for the use studied.
- ACHIEVE-PEDS: A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly and Company. Conditions: Diabetes Mellitus, Type 2. Investigational — not approved for the use studied.
- ADVANCE: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Eli Lilly and Company. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- RESTRAIN-SUI: A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Eli Lilly and Company. Conditions: Urinary Incontinence,Stress. Investigational — not approved for the use studied.
- ATTAIN-PAD: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
Eli Lilly and Company. Conditions: Peripheral Arterial Disease. Investigational — not approved for the use studied.
- ACHIEVE-RAM: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
Eli Lilly and Company. Conditions: Diabetes Mellitus, Type 2; Diabetes Melletus; Glucose Metabolism Disorders; Metabolic Disorders; Nutritional and Meta…. Investigational — not approved for the use studied.